By Reynaldo T. Acosta, Esq., Head of Litigation, Vitale, Suarez & Associates, P.A. · Miami Lakes, Florida
A Medicare clawback in wound care is not a denial. It is the recovery of money you already received, already deposited, and in most cases already spent buying the next order of product. If your practice bills high-cost skin substitutes, you need to understand that the appeal process pauses the recovery at two levels and then lets it resume at the exact level where you first get a hearing — which means the case and the cash flow are two separate problems that have to be solved at the same time.
A clawback is post-payment recoupment. A Medicare Administrative Contractor pays claims, reviews them afterward, determines an overpayment, and recovers it, generally by offsetting your future payments rather than sending you an invoice you could dispute before paying. For a wound care practice whose receivables are concentrated in one product line, that offset does not reduce revenue. It stops it.
Why Wound Care Sits Where It Sits
The exposure is not random. It follows from how these products were paid until the end of 2025.
The Office of Inspector General described the mechanism in a report issued September 3, 2025: “For payment purposes, CMS treats skin substitutes like approved prescription biologics and skin substitutes are reimbursed in non-institutional Part B settings at 106 percent of the average sales price (ASP).” Payment at a fixed percentage above a reported price, with a separate billing code per product.
The resulting spending is documented in the government’s own records. The Centers for Medicare & Medicaid Services states that Part B spending on these products “rose from $252 million in 2019 to over $10 billion in 2024, a nearly 40-fold increase”, and that “Most of that increase is directly attributable to increases in payment rates and launch prices for skin substitute products.” The OIG report found that “The average Part B payment amount for each unit of skin substitute increased by 153 percent”, and that in 2024 “these products accounted for over 15 percent of the $66 billion the program spent on all Part B drugs that year.”
Then the method changed. Under the CY 2026 Physician Fee Schedule final rule (CMS-1832-F, 90 FR 49266, effective January 1, 2026), CMS finalized paying for these products “as incident-to supplies when they are used as part of a covered application procedure.” The Department of Justice described the effect in June 2026: CMS “separately realigned payment, reducing Medicare’s payment to $127 per square centimeter starting on January 1, 2026.” The exact figure differs slightly between the physician and outpatient rules and is subject to geographic adjustment, so treat approximately one hundred twenty-seven dollars per square centimeter as the order of magnitude rather than a single national number.
What that history means for a clawback. The rate change is prospective and does not reprice an earlier claim. But it establishes, in the government’s own rulemaking, that the prior payment method produced growth the agency considered unsustainable — and post-payment review of the period before the change is the natural consequence. The payment shift itself is covered in the payment change and its impact on providers.
The Stay Exists, and It Is Narrower Than Providers Assume
This is the part to read carefully, because the common belief — that appealing stops the money from being taken — is only half right.
42 C.F.R. § 405.379 governs the limitation on recoupment. Three provisions matter.
First, there is a floor before recoupment starts. Contractors “can begin recoupment no earlier than 41 days from the date of the initial overpayment demand.” Forty-one days from the demand, not from your receipt of it.
Second, the stay attaches at two levels. A timely and valid request for redetermination causes the contractor to cease recoupment. A timely and valid request for reconsideration does the same. Both words matter: timely, and valid. A request filed late, or filed without the content the level requires, does not trigger the stay — and by the time anyone discovers the defect, the offset has already begun.
Third, and this is the provision that changes planning: § 405.379(d)(5) states that “if the provider or supplier subsequently appeals the overpayment to the ALJ, the Medicare Appeals Council, or Federal court, recoupment remains in effect.”
The stay does not reach the administrative law judge. It stops exactly where you first get a hearing before a decision-maker who is not the contractor.
Two further mechanics complete the picture. After a redetermination that confirms the overpayment, recoupment resumes “On the 60th calendar day after the date of the notice of redetermination.” And under § 405.379(d)(9), “Interest accrues and is payable in accordance with the provisions of § 405.378.” The debt does not sit still while you appeal.
The Consequence Nobody Budgets For
Put the provisions in sequence and the operating reality appears.
You receive a demand. You have a window before recoupment can begin. You file a timely redetermination and the offset pauses. You lose the redetermination — which is common, because it is reviewed by the same contractor organization that made the determination. Recoupment resumes on the sixtieth calendar day after that notice unless a timely, valid reconsideration is filed. You file it and the offset pauses again. You lose the reconsideration.
And now recoupment runs, with interest, for the entire time it takes to reach and complete an administrative law judge hearing. That is the period during which a provider actually gets a full evidentiary presentation, and it is the period during which the money is gone.
The planning implication is uncomfortable and unavoidable: a defense strategy that depends on prevailing at the administrative law judge level is a strategy that requires financing the interim. Providers who do not model that end up settling a case they could have won, for reasons that have nothing to do with the merits.
Three practical consequences follow.
Model the cash first. Take your monthly Medicare receipts, apply the offset, and run thirty, sixty, ninety and one hundred eighty days. Do it before you decide the appeal posture, not after.
Treat the first two levels as real, not as procedure. Because they are the only levels where the offset stops, they are worth full submissions rather than placeholder filings — even though the reviewer is affiliated with the contractor. A thin redetermination is not a free option; it is a spent one.
Ask about a repayment arrangement as a parallel track, not an admission. An extended repayment schedule is a cash instrument. Whether it is available and appropriate depends on the facts, and it does not resolve the merits — but the question belongs on the table early rather than after the offset has already broken payroll.
What the Contractor Is Actually Reviewing
The findings in this field are consistent, and every one of them is documentary.
Medical necessity for each application. The Department of Justice’s 2025 takedown announcement described allografts allegedly “applied without coordination with the patients’ treating physicians, without proper treatment for infection, to superficial wounds that did not need this treatment, and to areas that far exceeded the size of the wound.” Wound measurements over time, infection management, coordination with the treating physician, and the clinical basis for choosing that product are the four answers. The standard is discussed in medical necessity for wound care.
Quantity applied against wound size. The most arithmetically provable finding available. Product applied to an area larger than the documented wound, and the treatment of unused product, are examined in skin substitute wastage.
Frequency and the number of applications per patient. A course of treatment that continues without documented change in the wound invites the question of what the continued applications were achieving.
Place of service. The OIG found that “Among enrollees with a skin substitute claim, costs for those reportedly treated at home were four times as high as those treated in an office setting.” A home-based model is lawful and sometimes clinically necessary. It is also a documented outlier characteristic, which means the supporting record has to be stronger than average rather than thinner.
Whether the records were contemporaneous. A note written accurately weeks later describes the same session and satisfies a different standard than a note made at the time. In an electronic record, creation and edit timestamps establish which happened, regardless of the date the note displays.
Extrapolation: Where a Small Sample Becomes a Large Demand
A wound care clawback is frequently not proportional to the charts reviewed, and the reason is statistical rather than clinical.
When a contractor reviews a sample and projects the error rate across a larger universe of paid claims, a recurring defect in a handful of files becomes a demand tied to hundreds. That changes what you are defending. You are no longer arguing about thirty patients; you are arguing about the validity of the projection and about the claim-level determinations that fed it.
The strongest posture usually attacks both at once: the individual determinations in the sample, because correcting even a few can materially move the projected total, and the methodology itself — the definition of the universe, the sampling frame, the sample size and stratification, and the classification of each alleged error. The mechanics are set out in challenging the extrapolation methodology used in large-scale audits, and the appeal pathway for denied wound care claims in appealing wound care denials.
The Clawback Does Not Stay a Payment Problem
Two escalation paths run out of an unresolved overpayment, and both are worth understanding before you choose how to respond.
The reverse false claim. Under 31 U.S.C. § 3729(a)(1)(G), liability reaches a person who “knowingly conceals or knowingly and improperly avoids or decreases an obligation to pay or transmit money or property to the Government.” Section 3729(b)(3) defines “obligation” broadly, as “an established duty, whether or not fixed.” An identified overpayment that is not addressed can become a False Claims Act theory rather than remaining a collections matter. That transition is examined in how unresolved overpayments become False Claims Act exposure.
The knowledge standard, which is lower than most providers expect. Section 3729(b)(1) defines “knowingly” to include a person who “acts in deliberate ignorance of the truth or falsity of the information” or who “acts in reckless disregard of the truth or falsity of the information”, and the definitions “require no proof of specific intent to defraud.” Deliberate ignorance is the standard that reaches a provider who accepted a distributor’s assurances about coverage without independent verification.
And there is a third path that is not about you at all. A clawback tells a distributor that its invoices are not going to be paid, which is frequently what precipitates a collection suit against the practice. That interaction is the subject of what happens when the skin substitute distributor sues you, and the way all three proceedings interlock is set out in skin graft fraud litigation and the three fronts.
Immediate Response Checklist
Read the demand and identify what it actually is: a preliminary finding, a final overpayment determination, or a notice that recoupment has begun. Calendar the deadline stated in the document, with a named owner, and calendar the forty-one day floor and the sixty-day resumption date alongside it. Determine whether the amount rests on a projection or on claim-level findings only. Preserve every record as it stands, without amendment — charts, wound photographs and measurements, purchase orders, invoices, and communications with sales representatives. Model the cash position with the offset applied. Decide the appeal posture with that model in front of you. Route external communication through one person, and instruct staff not to volunteer explanations in writing or by phone.
One action to avoid: supplementing or correcting a chart after the demand arrives. Retrospective documentation is more dangerous than the gap it was meant to close, because it converts a coverage dispute into a question about the integrity of the record. That line is examined in the difference between a billing error and an allegation of fraud.
When Early Counsel Is Not Optional
A clawback is a payment matter until it is not, and the signals that it has become something else are usually visible in the paperwork. A demand that reaches back across multiple years, one that arrives with a records request covering patients outside the sample, one that references documentation integrity rather than medical necessity, or one that arrives alongside a civil investigative demand or a payment suspension — each of those indicates a proceeding wider than a single overpayment.
Early legal review helps preserve the appeal record at the two levels where the stay actually operates, keep the payment-side submissions consistent with anything you may later have to say in a federal matter, and protect internal analysis under attorney-client privilege where applicable. Where counsel directs the review, communications about suspected legal exposure and response strategy may be better protected than informal exchanges among clinical, billing and administrative staff.
Vitale, Suarez & Associates, P.A. has represented healthcare providers and other defendants in wound care and skin substitute matters, including audit and overpayment proceedings, commercial disputes with product suppliers, and government investigations. Nothing in this article describes any particular client, matter, or outcome. The firm’s practice in Medicare and Medicaid overpayments and defense investigations is described among its practice areas.
Frequently Asked Questions
Does filing an appeal stop a Medicare clawback?
At the first two levels only. Under 42 C.F.R. § 405.379, a timely and valid request for redetermination causes the contractor to cease recoupment, and a timely and valid reconsideration request does the same. Section 405.379(d)(5) provides that recoupment remains in effect once the matter proceeds to an administrative law judge, the Medicare Appeals Council, or federal court.
How soon can recoupment begin?
Section 405.379 provides that contractors can begin recoupment no earlier than 41 days from the date of the initial overpayment demand.
When does recoupment resume after an unfavorable redetermination?
On the 60th calendar day after the date of the notice of redetermination, unless a timely and valid reconsideration request is filed.
Does interest accrue while we appeal?
Yes. Section 405.379(d)(9) provides that interest accrues and is payable in accordance with 42 C.F.R. § 405.378.
Can a review of thirty charts produce a demand covering hundreds of claims?
It can, where the contractor projects a sample error rate across a larger universe of paid claims. In that situation the projection itself is part of what is being defended, alongside the individual claim determinations.
Did the 2026 payment change create the clawback risk?
No. The change in payment method is prospective and does not reprice earlier claims. Post-payment review of the earlier period rests on the standards that applied at the time — medical necessity, documentation, and the quantity billed against the wound treated.
The decision rule is simple: the stay ends where the hearing begins, so model the cash before you choose the posture. A case you can win and cannot finance is not a plan.
This article is for general information purposes only and should not be taken as legal advice for any individual case or situation. Reading it, or corresponding with us through this site, is not intended to create and does not create an attorney-client relationship. Federal and Florida healthcare regulations change frequently, and how any rule applies depends on the specific facts of your arrangement, your payor contracts, and your jurisdiction. Vitale, Suarez & Associates, P.A. is based in Miami Lakes, Florida and represents clients in Florida. If you have received an audit notice, records request, subpoena, civil investigative demand, or overpayment demand, speak with a licensed attorney before you respond.
Past results do not guarantee or predict a similar outcome in any future matter. Every case depends on its own facts. Charges and allegations referenced in government announcements are accusations only; a charge is not a conviction.
About the author. Reynaldo T. Acosta heads the litigation practice at Vitale, Suarez & Associates, P.A. in Miami Lakes, Florida, the firm founded in 1982 as The Health Law Offices of Anthony C. Vitale, P.A. He is a member of The Florida Bar and earned his J.D. from Florida International University College of Law, where he was named to the Dean’s List and competed on the International Commercial Arbitration and the Negotiation and Mediation teams. He also holds advanced certifications in generative artificial intelligence, machine learning, and agentic systems from IBM, Anthropic, and Microsoft. He is a member of the American Bar Association, the Hispanic National Bar Association, and the Cuban American Bar Association, and works with clients in English and Spanish. More about the firm and its attorneys is available on the firm’s About page.
Contact Our Healthcare Lawyers Today!
Schedule a Consultation: (305) 358-4500
Contact Us
Vitale, Suarez & Associates, P.A.
8100 Oak Ln Suite 403
Miami Lakes, FL 33016
Phone: (305) 358-4500
Fax: (305) 358-5113
Email: info@vitalehealthlaw.com
Hours: Monday through Friday, 9:00 a.m. to 5:00 p.m.
The firm’s attorneys work with clients in English and Spanish.